Get ahead of it! Will these "heavy-weight drugs" Q3 be available for multinational drug companies?

Guide: In addition to the Covid-19 vaccine, Q3 multinational drug companies in 2020 have these major research and development progress to see.June, immediately into the third quarter of 2020, in addition to Covid-19-related vaccines and therapeutic drugs or ushered in the first wave of data release, YanJian, Sanofi, BMS, Lilly and other multinational pharmaceutical companies will also be a number of heavy-weight drugs to release the latest clinical data. While the number of products in the pipeline of the world's top pharmaceutical companies has fallen to its lowest level in a decade this year, the market value of the remaining products in the next 5-10 years remains unnegligible.recently, the Evaluate Vantage website summarized the future of "heavy-duty drugs" and their progress by large pharmaceutical companies in Q3 this year.
Aducanumab: . Alzheimer's disease2026 projected sales: $2,987 millionQ3 event 2020: Expected to complete approval for listingOctober 2019, based on the reanalysis of two Phase 3 clinical studies data, Engage and Emerge, Bio The high dose of aducanumab, which has reached the primary endpoint, reduces cognitive decline by 23% (p-0.01), improves patients' cognitive abilities such as memory, direction, and language, and improves patients' daily abilities such as cleaning, shopping, laundry and going out alone. This has given hope to the Alzheimer's disease field, where investment has been almost completely unsuccessful for more than a decade, but whether aducanumab can be approved is uncertain because clinical data are too limited. In April this year, Mr Yan made a further proposal to delay the submission of a listing application.but even if the data is not strong enough, Yan Jian is afraid that at present, I am afraid that the new drug of Alzheimer's disease can only be bet. That's because just last week, the company's heavyweight multiple sclerosis drug, Tecfidera, lost its eight-year market share in a patent battle with Mylan, which accounted for 39 percent of total sales in 2019. Therefore, Yan Jian urgently needs a heavy new drug to make up for the loss of patents.
hundred-time Mesiquibo/Bluebird Creatures (BMS/Bluebird) Ide-cel: Multiple myeloma (MM) . Estimated 2026 sales: $1,452 millionQ3 event s2020: Resubmit listing applications by the end of JulyIde-celidecabagene vicleucel is the first to submit regulatory approval for BCMA targets and CAR-T cell therapy for the treatment of MM. BMS and Bluebird Filed filed a bioproduct license (BLA) application for bioproduct licensing for MM adult patients who have received at least three treatments, including immunomodulators, protease inhibitors, and anti-CD38 antibodies, to the FDA in March. In May, the FDA received a rejection notice that the chemical, manufacturing and control modules in its application needed to provide further details.. MM is the second most common hematologic malignancy after non-Hodgkin's lymphoma. Although much progress has been made in the therapies of chemotherapy, protease inhibitors, immunomodulator thalidomide derivatives and CD38-targeted antibodies, almost all patients will still relapse. The MM market is expected to reach $29 billion by 2027.
Gilead Yescarta: . Dispersive large B cell lymphoma2026 estimated sales: $1,331 million2020 Q3 events: Phase 3 clinical Zuma-7 study data releasedJanuary 2018, CAR-T therapy Yescarta (axicabtageneecelu) received FDA approval for treatment of patients with at least two other treatments that have not been alleviated or relapsed from the disease. But Gilead wanted to expand the use of Yescarta's treatment for lymphoma from three to two lines, so the approval was also launched on the launch of Yescarta and standard therapy (SOC) to compare the treatment of recurrent/refractable diffuse large B cell lymphoma phase 3 clinical study ZUMA-7 (NCT03391466), enrolled in the group of 359 first-line treatment patients receiving litoxaanda and treatment-based chemotherapy., according to Gilead's earnings, Yescarta's total sales in 2019 were $456 million, up 72.7 percent from $264 million in 2018. But Yescarta's profitability has not been as profitable as it was expected to be compared with its $11.9 billion acquisition of Kite Pharmaceuticals. In December 2019, Fosun Kate, which is responsible for The meppartation of Yescarta China, officially launched its first CAR-T industrialization production base, which will further open the treatment to the Chinese market.
UCB Bimekizumab: . Psoriasis2026 Estimated Sales: $947 million2020 Q3 Events: Phase 3 Clinical BE RADIANT Research Data Release Bimekizumab is a new type of human-derived monoclonal IgG1 antibody that can powerfully, selectively neutralize IL-17A and IL-17F, two key cell factors that drive the inflammatory process. This unique IL-17A/IL-17F double inhibition may provide a new targeted therapy for the treatment of immune-mediated inflammatory diseases.two phase 3 clinical studies, BE VIVID and BE READY, released in June this year, showed that bimekizumab showed better skin removal in the 16th week of treatment than receiving placebo or Johnson IL-12/IL-23 inhibitor Stelara (ustekinumab, ustekzumab) treatment, and that most patients completely removed the skin loss for one year.but The goal of Uber bimekizumab seems to be to prove that it can surpass all products in the psoriasis market through head-to-head tests. In addition to Stelara, Usbiti also plans clinical studies on AbbVie Humira, Skyrizi and Novartis Cosentyx to make Bimekizumab a new growth driver and a strong market competitor for Uber. This fall, be-RADIANT, a research on the efficacy and safety of severe chronic plaque psoriasis in the head-to-head treatment of bimekizumab and Cosentyx head-to-head therapy, will be published.
AstraZeneca Imfinzi and tremelimab: . First-line treatment of liver cancer 2026 estimated sales: $124 million 2020 Q3 event: Phase 3 Clinical Himalaya Research Data Release Phase 3 Clinical Trial Himalaya is evaluated anti-PD-L1 monoanti-Imfinzi (durvalumab) single drug, IMFin The combination of zi and anti-CTLA4 therapy tremelimumab, compared to the standard therapeutic drug Nexavar (sorafenib, sorafenib), is used to treat patients with non-resectionable, advanced hepatocellular carcinoma (HCC) who have previously not been treated with a system and are not eligible for local region therapy. AstraZeneca is expected to soon receive its first-line liver cancer analysis to combat Bayer's multikinase inhibitor Nexavar. Earlier june, the first immunotherapy for first-line treatment for liver cancer was approved, and the Tecentriq joint Avastin treatment from Roche was approved. Based on Imbrave-150 research data, Tecentriq-Avastin combined drugs can reduce the risk of death by 42% compared to Nexavar (p.0006) and a 41% risk of disease deterioration or death (p.0001). As aurerie is also looking forward to Himalaya's comparison results in January 2020. Limumab has been granted the FDA treatment of HCC orphan medicine.
Health BIIB054 (cinpanemab): Parkinson's disease estimated sales in 2026: $26 million 2020 Q3 event: Phase 2 clinical Spark research data published Parkinson's brain cells in patients with a protein aggregation, this toxicity in the middle cells. These toxic proteins are thought to spread from one cell to another, gradually leading to an increase in damage. BIIB054 is an anti-alpha-synaptic nucleoprotein monotophox that is specifically attached to alpha-synaptic nucleoproteins to prevent the transmission of toxic proteins, thereby controlling the deterioration of Parkinson's disease. current Phase 2 clinical trial Spark (NCT03318523) is currently under way, with the primary endpoint being drug safety, and the secondary endpoint is biIB054's pharmacodynamic effect on dopamine nerves, as well as pharmadynamics and immunogenicity.
Sanofi Thor-707: . Solid tumor 2026 projected sales: $11 million 2020 Q3 event: 1/2 clinical Hammer research data released in December 2019, Sanofi's $2.3 billion acquisition of Synthorx for improved version of leukocyte interleukin-2 (IL-2) Thor-707 is expected to obtain phase 1/2 clinical trial results in the second half of this year. Il-2 therapy, which improves the level of CD8 plus T cells that can detect and kill tumor cells, was approved by the U.S. FDA 25 years ago for multiple metastatic cancer treatments. However, due to its short half-life, multiple injections may have side effects. Thor-707 is designed to improve the half-life of the IL-2 protein by introducing polyglycol modification at specific sites of the human IL-2 protein, while avoiding the risk of vascular leakage syndrome. Sanofi believes thor-707 is expected to be the basis for future immuno-oncology (I/O) combination therapies. The current Hammer study focuses on the toxicity of the experimental drug. . Thor-707 is under study as a single drug and does not specify a combination of PD-(L) 1 drugs, such as Sanofi Libtayo, for solid tumors. Libtayo was approved in 2018 as a late-comeor in the highly competitive PD-(L) 1 market, and the combination with Thor-707 could make a difference. The treatment of IL-2 combined PD-(L)1 inhibitors is thought to enhance the response of CD8-T cells and has a greater anti-tumor effect than point-of-a-point inhibitors. . BMS/Ambrx Pegbelfermin: non-alcoholic fatty hepatitis (NASH) 2026 estimated sales: $7 million 2020 Q3 event: Phase 2 Clinical Falcon 1 Study Released Pegbelfermin (BMS-986036) is a polyethylgylgol A similar ity of fibroblast growth factor 21 (FGF21), previously conducted in a phase 2a clinical study (NCT02413372), showed a significant decrease in the absolute content of liver fat 16 weeks after treatment with non-alcoholic fatty hepatitis with a BMI of more than 25 kg/m2. Pegbelfermin had an absolute liver fat score of 6.8 per cent for patients in the 10mg group per day, 5.2 per cent in the 20mg group per week, compared with 1.3 per cent in the placebo group. In addition, subcutaneous injections are well tolerated. later this year, the 2b clinical results of pegbelfermin for adult NASH and phase 3 liver fibrosis research FALCON 1 will be published. At the same time, the drug for long-term research on adult NASH and cirrhosis falcon 2 will also be initially completed in September. the current SIZE of the NASH market has reached $40 billion, the layout of the NASH field of many pharmaceutical companies, but so far no drugs have been approved, the world's fastest progress is intercept Pharma obeticholic acid acid, originally scheduled to complete the listing in March this year, but the FDA delayed the decision, presumably related to drug safety.
Lilly Mevidallen/LY3154207 (D1 PAM): . Lewy Body Dementia 2026 estimated sales: $5 million 2020 Q3 events: Preliminary completion of Phase 2 clinical study in July LY3154207 is a subtype selective, oral human dopamine D1 receptor (HUMAN dopamine D1 receptor) positive regulator (PAM), originally developed for the treatment of Parkinson's disease (PD). Similar to PD, Louisian dementia is a slow-progressing neurodegenerative disease whose clinical and pathological manifestations overlap with PD and Alzheimer's disease. . LY3154207 is caused by Louis' dementia or associated with a dyslest PD.